Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

Author information

Affiliations

  • 1. Philipps Universität Marburg, Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Hämatologie, Onkologie und Immunologie, Marburg, Germany.
      Authors
    • Metzelder SK 1
    • Wollmer E 1
    • Neubauer A 1
    • Burchert A 1
    (4 authors)
  • 2. University of Duesseldorf, Medical Faculty, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany.
      Authors
    • Schroeder T 2
    • Kobbe G 2
    (2 authors)
  • 3. University of Freiburg, Department of Hematology/Oncology, Freiburg, Germany.
      Authors
    • Lübbert M 3
    • Finck A 3
    • Finke J 3
    (3 authors)
  • 4. Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Germany.
      Authors
    • Ditschkowski M 4
    (1 author)
  • 5. Department of Internal Medicine III, Technische Universität München, Munich, Germany.
      Authors
    • Götze K 5
    (1 author)
    • Show all (12)

ORCIDs linked to this article

European Journal of Cancer (Oxford, England : 1990), 18 Oct 2017, 86:233-239
https://doi.org/10.1016/j.ejca.2017.09.016 PMID: 29055209 

Abstract 

Background

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.

Methods

We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.

Findings

With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.

Interpretation

Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.ejca.2017.09.016

Citations & impact 

Impact metrics

32
Citations
Jump to Citations
7
Data citations
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/27786428
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/27786428

Article citations

Go to all (32) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Deutsche Forschungsgemeinschaft, Klinische Forschergruppe 210 ‘Genetics of Drug resistance in Cancer’

    Deutsche José Carreras Leukämiestiftung (1)